Human cancers often related to signal pathway variation, the phosphoinositide-3-kinase (PI3K) pathway is one of it. AKT kinase family is the most common downstream of PI3K pathway. The serum and glucocorticoid kinase 2(SGK2) is similar to AKT as the downstream of PI3K pathway. Up to now, we have few understanding of SGK2 in colon cancer. We determined the 20 colon cancer samples mRNA level. Later, we silence SGK2 in colon cancer cells. We found that SGK2 is up-regulated in colon cancer tissue/cells and have positive correlation with cell migration and invasive potential in human colon cancer cell line CACO2 and HCT116. The expression level of SGK2 have positive correlation with expression of mesenchymal marker N-cadherin and Vimentin and negative correlation with the expression of epithelial marker E-cadherin in CACO2 and HCT116 cells. In short, our research indicate that SGK2 is overexpressed in colon cancer and promotes EMT in colon cancer cells.

目的:探讨多烯磷脂酰胆碱注射液联合注射用丁二磺酸腺苷蛋氨酸治疗胆汁淤积性黄疸患者的疗效.方法:选取胆汁淤积性黄疸患者62例,随机数字表法分为观察组与对照组.对照组予以注射用丁二磺酸腺苷蛋氨酸治疗,观察组在此基础上予以多烯磷脂酰胆碱注射液.统计两组治疗总有效率、不良反应发生率,并对比两组治疗前后肝功能指标水平.结果:观察组治疗总有效率高于对照组;观察组治疗后AST、TBil、ALT、DBil水平低于对照组;差异有统计学意义(P＜0.05);两组不良反应发生率比较无统计学差异(P＞0.05).结论:对胆汁淤积性黄疸患者联合采用注射用丁二磺酸腺苷蛋氨酸、多烯磷脂酰胆碱注射液治疗,可显著改善患者肝功能,提高治疗效果,且安全性高,值得临床推广应用.

Objective:To investigate the influence of different virological response states on survival rate and incidence of liver cancer in patients with decompensated hepatitis B virus (HBV) cirrhosis.Methods:A total of 142 patients with decompensated hepatitis B cirrhosis in Zhoukou Central Hospital from March 2017 to September 2019 were selected. According to the continuous measurability of HBV-DNA during the treatment of antiviral therapy, 90 patients with persistent virological response were allocated into group A, and 52 patients without persistent virological response were allocated into group B. The one-year cumulative incidence of liver cancer and the survival rate without liver transplantation were compared between the two groups, and the one-year cumulative incidence of liver cancer and survival without liver transplantation were compared among patients treated with different drugs.Results:The one-year cumulative incidence of liver cancer in group A was 1.11%(1/90), which was lower than that in group B (7.67%, 4/52), and the difference was statistically significant ( P<0.05). The one-year non liver transplantation survival rate in group A was 98.89%(89/90), which was higher than that in group B (92.31%, 48/52), and the difference was statistically significant ( P<0.05). There was no significant difference in one-year non liver transplantation survival rate or cumulative incidence of liver cancer in patients with decompensated hepatitis B cirrhosis treated with different drugs ( P>0.05). Conclusions:Antiviral therapy can improve the prognosis of patients with decompensated hepatitis B cirrhosis, which can not be affected by the drug difference. The continuous virological response can reduce the incidence of liver cancer, and improve the survival rate of patients without liver transplantation.